Restrictive vs Liberal Intraoperative Fluid Strategy and Postoperative Outcomes After Elec
Spinal anesthesia for elective cesarean section is frequently associated with hemodynamic instability and postoperative complications such as postoperative nausea and vomiting (PONV) and delayed gastrointestinal recovery. Although intraoperative fluid administration is routinely used to prevent spinal-induced hypotensi
| Condition(s) | Cesarean Section, Postoperative Nausea and Vomiting (PONV), Postdural Puncture Headache (PDPH), Postoperative Ileus, Gastrointestinal Recovery |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Spinal anesthesia for elective cesarean section is frequently associated with hemodynamic instability and postoperative complications such as postoperative nausea and vomiting (PONV) and delayed gastrointestinal recovery. Although intraoperative fluid administration is routinely used to prevent spinal-induced hypotension, the optimal fluid strategy remains unclear. Both restrictive and liberal fluid approaches may influence maternal hemodynamics and postoperative outcomes through different physiological mechanisms. This prospective, single-center, randomized controlled trial aims to compare restrictive (≤3 mL/kg/h) and liberal (\>3 mL/kg/h) intraoperative crystalloid fluid strategies in patients undergoing elective cesarean section under spinal anesthesia. The primary outcome is the incide |
| Who can participate | Inclusion Criteria: * Female patients aged 18-45 years * ASA physical status II * Scheduled for elective cesarean section under spinal anesthesia * Provision of written informed consent Exclusion Criteria: * Emergency cesarean section * Preeclampsia or eclampsia * Known cardiac failure * Known renal failure * Known hepatic failure * Coagulopathy * Contraindication to spinal anesthesia * Conversion to general anesthesia * Major technical complications during spinal anesthesia * Refusal to participate |
| Ages | 18 Years to 45 Years |
| Sex | Female |
| Lead sponsor | Nigde Omer Halisdemir University |
| Locations | Niğde, Merkez, Turkey (Türkiye) |
| Start date | 2026-03-04 |
| NCT ID | NCT07440667 |
| Official listing | https://clinicaltrials.gov/study/NCT07440667 |